1430063-08-3

Basic information

• Product Name: C₂₀H₃₂O₃
• CAS NO: 1430063-08-3
• Molecular Weight: 320.472
• Mol File: 1430063-08-3.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: C₂₀H₃₂O₃(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₀H₃₂O₃(1430063-08-3)
• EPA Substance Registry System: C₂₀H₃₂O₃(1430063-08-3)

Safety Data

• Hazardous Substances Data: 1430063-08-3(Hazardous Substances Data)

Upstream product

• 5696-51-5 5β-estrane-3,17-dione 
• 734-32-7 estra-4-ene-3,17-dione 
• 67-56-1 methanol 

Downstream Products

• 1430063-93-6 2-bromo-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethan-1-one 
• 1430063-26-5 C₂₇H₃₆F₂O₃S 
• 1430063-95-8 C₂₇H₃₆F₂O₃S 

Relevant articles and documents

Steroid compound, application and preparation method thereof

The invention relates to a steroid compound, an application and a preparation method thereof. The compounds are expected to be capable of effectively treating neuropsychiatric diseases, and have goodactive efficacy, pharmacokinetic (PK) performance, oral

COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS

Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b

C17, C20, AND C21 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE

Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.